CBD shows promise in models, but human disease modification remains unproven
Phytocannabinoid cannabidiol (CBD) in neurodegenerative diseases: From polypharmacology to drug development.
AI Summary
This abstract-based summary describes a review of cannabidiol (CBD) as a potential multi-target treatment candidate for neurodegenerative diseases. It brings together evidence from preclinical models of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, and amyotrophic lateral sclerosis, alongside preliminary clinical evidence. The review examines how CBD may influence neuroinflammation, excitotoxicity, mitochondrial dysfunction, impaired protein handling, and synaptic injury through several signaling systems, including cannabinoid receptors, ion channels, serotonin and adenosine pathways, and redox regulation.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.